Clinical and Population Studies

Plasma Apolipoprotein C-III Levels, Triglycerides, and Coronary Artery Calcification in Type 2 DiabeticsSignificance

Arman Qamar, Sumeet A. Khetarpal, Amit V. Khera, Atif Qasim, Daniel J. Rader, Muredach P. Reilly
https://doi.org/10.1161/ATVBAHA.115.305415
Arteriosclerosis, Thrombosis, and Vascular Biology. 2015;35:1880-1888
Originally published June 11, 2015

Jump to

Abstract

Objective—Triglyceride-rich lipoproteins have emerged as causal risk factors for developing coronary heart disease independent of low-density lipoprotein cholesterol levels. Apolipoprotein C-III (ApoC-III) modulates triglyceride-rich lipoprotein metabolism through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoproteins. Mutations causing loss-of-function of ApoC-III lower triglycerides and reduce coronary heart disease risk, suggestive of a causal role for ApoC-III. Little data exist about the relationship of ApoC-III, triglycerides, and atherosclerosis in patients with type 2 diabetes mellitus (T2DM). Here, we examined the relationships between plasma ApoC-III, triglycerides, and coronary artery calcification in patients with T2DM.

Approach and Results—Plasma ApoC-III levels were measured in a cross-sectional study of 1422 subjects with T2DM but without clinically manifest coronary heart disease. ApoC-III levels were positively associated with total cholesterol (Spearman r=0.36), triglycerides (r=0.59), low-density lipoprotein cholesterol (r=0.16), fasting glucose (r=0.16), and glycosylated hemoglobin (r=0.12; P<0.0001 for all). In age, sex, and race-adjusted analysis, ApoC-III levels were positively associated with coronary artery calcification (Tobit regression ratio, 1.78; 95% confidence interval, 1.27–2.50 per SD increase in ApoC-III; P<0.001). As expected for an intermediate mediator, these findings were attenuated when adjusted for both triglycerides (Tobit regression ratio, 1.43; 95% confidence interval, 0.94–2.18; P=0.086) and separately for very low–density lipoprotein cholesterol (Tobit regression ratio, 1.14; 95% confidence interval, 0.75–1.71; P=0.53).

Conclusions—In persons with T2DM, increased plasma ApoC-III is associated with higher triglycerides, less favorable cardiometabolic phenotypes, and higher coronary artery calcification, a measure of subclinical atherosclerosis. Therapeutic inhibition of ApoC-III may thus be a novel strategy for reducing plasma triglyceride-rich lipoproteins and cardiovascular risk in T2DM.

Introduction

Currently, the paradigm for the prevention and treatment of coronary heart disease (CHD) is lowering circulating low-density lipoprotein cholesterol (LDL-C) through statins and other therapies.1 Although statins are highly efficacious in lowering LDL-C and vascular risk, significant residual risk remains for many. Also, many at-risk patients are intolerant to the adverse effects of these drugs. Plasma TG have emerged as independent predictor of cardiovascular risk, as evidenced by multiple prospective epidemiological studies.2,3 Recent human genetics studies have given credence to the concept that triglyceride-rich lipoproteins (TRLs) may be causally related to cardiovascular risk.4,5 Genetic variation in several genes in the lipoprotein lipase pathway of plasma triglyceride hydrolysis is associated with triglyceride levels and CHD risk.6–10 Among the genes implicated in these studies is APOC3, which encodes apolipoprotein C-III (ApoC-III).4,6,7

ApoC-III is a small protein (8.8 kDa) that is secreted from the liver and small intestine.11 ApoC-III circulates in the blood on very LDLs (VLDLs), chylomicrons, and high-density lipoproteins (HDLs). Animal models and biochemical studies have shown that ApoC-III inhibits the turnover of plasma triglycerides through potentially multiple synergistic mechanisms, including inhibition of lipoprotein lipase activity, delay of hepatic clearance of TRLs, and promotion of VLDL secretion.12–18 In humans, genetic loss-of-function of APOC3 is associated with lower plasma triglycerides and a reduced risk of CHD and coronary calcification.6,7,19 Investigations of rare coding variants in APOC3 have shown that CHD-protective variants reduce circulating ApoC-III levels. These studies suggest that inhibition of ApoC-III may reduce vascular risk.

The molecular regulation of ApoC-III expression and circulating levels in metabolic disease states is complex. Several nutrient- and metabolite-activated hepatic transcription factors, including HNF4α (hepatocyte nuclear factor 4 alpha), PPARα (peroxisome proliferator-activated receptor alpha), Rev-Erbα (nuclear receptor subfamily 1, group D, member 1 [NR1D1]), RORα (retinoic acid receptor [RAR]-related orphan receptor alpha), and FXR, may either positively or negatively regulate Apoc3 transcription in rodent hepatocytes.17,20–27 Studies in a mouse model of insulin resistance demonstrated that Apoc3 gene expression increases in response to glucose via HNFα- and ChrEBP (carbohydrate response element binding protein)-mediated transcription.27 Apoc3 expression decreases with insulin or fibrate stimulation in vitro.20,22,26,28 However, plasma ApoC-III levels are not correlated with plasma insulin in humans.17,27 It has been suggested that glucose-mediated induction and insulin-mediated suppression of hepatic APOC3 expression may normally balance each other to regulate the total amount of ApoC-III secreted from the liver.17,27 Likewise, in the insulin-resistant state, the sensitivity of APOC3 expression to insulin may be lost and in the concomitant setting of hyperglycemia there may be unopposed activation of APOC3 expression and increased ApoC-III secretion on TRLs. This mechanism of perturbed TRL metabolism may modulate insulin resistance and cardiovascular risk in multifaceted ways.

The majority of studies of ApoC-III, triglycerides, and CHD risk to date have been conducted in nondiabetic subjects. However, CHD is prevalent in patients with type 2 diabetes mellitus (T2DM) and is indeed the leading cause of death in this population.29 Insulin resistance and T2DM are characterized by alterations in TRL metabolism.30 In addition, the expression of APOC3 is regulated by both insulin and glucose.17,20,22,27,28 Thus, the relationship of ApoC-III to TRL metabolism and CHD in T2DM is of substantial importance. Here, we studied a sample of 1422 subjects with T2DM but without clinical CHD for the relationship of plasma ApoC-III levels with triglycerides, related metabolic biomarkers, and coronary artery calcification (CAC), a measure of subclinical atherosclerosis.

Materials and Methods

Materials and Methods are available in the online-only Data Supplement.

Results

Characteristic of Participants

The characteristics of the study population are described in Table 1. Study participants (n=1422) were predominantly males of white descent. Subjects had a median age of 59 years at the time of enrollment. Mean plasma ApoC-III levels were 12.5±10 mg/dL, with a median of 11.3 mg/dL (Figure 1). Subjects of African ancestry had lower ApoC-III levels than those of European ancestry (10.9±12.4 versus 13.5±10; P<1×10−3, Table 1; Table I in the online-only Data Supplement). ApoC-III levels were significantly lower in women than men (11.8±11 versus 13±10 mg/dL; P<0.05; Table 1).

View this table:
Table 1.

Characteristics of Study Participants

Figure 1.
Figure 1.

Distribution of plasma apolipoprotein C (ApoC)-III levels in study participants. Plasma ApoC-III levels were measured by an immunoturbmidimetric assay as mentioned in the Materials and Methods section of this article. ApoC-III levels were measured in a total of 1422 subjects.

Association of ApoC-III Levels With Lipid-Related Traits

We found a significant positive association of ApoC-III levels with triglycerides (Spearman correlation coefficient r=0.59; P<1×10−4; Table 2). This association remained significant even after adjusting for age, sex, race, body mass index (BMI), alcohol use, glomerular filtration rate, exercise, use of lipid-lowering, and hypoglycemic medications in a linear regression analysis model (β=0.57; P<1x10−4; Table 3). In a multivariate linear regression model stratified by sex, we found that triglyceride levels were significantly associated with ApoC-III levels in both sexes (women, β=0.53; P<1×10−4 and men, β=0.60; P<1×10−4; Table 3).

View this table:
Table 2.

Correlation of ApoC-III Levels With Plasma Lipids and Cardiometabolic Phenotypes

View this table:
Table 3.

Association of ApoC-III With Plasma Triglycerides

We found a positive correlation of ApoC-III levels with plasma levels of total cholesterol (Spearman correlation coefficient r=0.36; P<1×10−5), LDL-C (Spearman correlation coefficient r=0.16; P<1×10−5), ApoB (Spearman correlation coefficient r=0.34; P<1×10−5), and ApoE (Spearman correlation coefficient r=0.25; P<1×10−5; Table 2). These findings were significant after adjusting for age, sex, race, BMI, smoking, alcohol use, and use of lipid-lowering, and hypoglycemic medications in linear regression (Table II in the online-only Data Supplement). Plasma ApoC-III levels were inversely correlated with HDL-C (Spearman correlation coefficient r=−0.06; P<0.05) and ApoA-I levels (Spearman correlation coefficient r=−0.16; P<1×10−5; Table 2). After adjustment for age, sex, and race, the association between ApoC-III levels with HDL-C attenuated but the association with ApoA-I remained significant (Table II in the online-only Data Supplement).

Relationship of ApoC-III Levels With Glycemic and Metabolic Traits

Plasma ApoC-III levels correlated positively with glycosylated hemoglobin (Spearman correlation coefficient r=0.12; P<1×10−5) and fasting glucose levels (Spearman correlation coefficient r=0.16; P<1×10−5), 2 metrics of glucose homeostasis (Table 2). These associations remained significant after adjusting for age, sex, and race in linear regression (Table III in the online-only Data Supplement). There was no association of ApoC-III levels with plasma fasting insulin. We stratified the analysis of ApoC-III levels with fasting glucose and hemoglobin A1c (HbA1c) by plasma triglyceride levels (Table III in the online-only Data Supplement) and found that the association was significant in subjects with elevated triglycerides (>150 mg/dL) but not in those with normal triglycerides (<150 mg/dL). To determine if this association might be dependent on the effect of ApoC-III on plasma triglycerides, we examined the association of ApoC-III with both HbA1c and fasting glucose before and after adjusting for plasma triglycerides (Table 4). There was no significant association of both HbA1c and fasting glucose with ApoC-III levels after adjusting for triglycerides in both sexes (women, β=−0.006; P=0.86 and men, β=0.05; P=0.37; Table 4).

View this table:
Table 4.

Association of ApoC-III With Glucose Phenotypes

In sex-stratified analysis of the relationship of ApoC-III with waist circumference, we found no association in women (Spearman correlation coefficient r=0.05; P=0.05) but a modest association with increased waist circumference in men (Spearman correlation coefficient r=0.07; P=0.03; Table 2). However, ApoC-III levels were not significantly associated with BMI in the combined sample (Spearman correlation coefficient r=−0.01; P=0.70; Table 2).

Association of ApoC-III Levels With CAC

In age, sex, and race-adjusted Tobit conditional regression of ln (CAC+1; Table 5), higher plasma ApoC-III was also associated with increasing CAC scores (Tobit regression ratio, 1.78; 95% confidence interval [CI], 1.27–2.50; P<0.001); this association remained significant after adjusting for smoking, glomerular filtration rate, BMI, alcohol, C-reactive protein, systolic blood pressure, history of hypertension, and use of all lipid-lowering and hypoglycemic medications (Tobit regression ratio, 1.91; 95% CI, 1.32–2.74; P<0.01; Table 5). The association with CAC was attenuated, losing statistical significance, after including triglycerides in the multivariate model (Tobit regression ratio, 1.43; 95% CI, 0.94–2.18; P=0.086). Similarly, when VLDL-C was included in the multivariate model including demographics and all medications, the association between ApoC-III and CAC was even more attenuated (Tobit regression ratio, 1.14; 95% CI, 0.75–1.71; P=0.53). Consistent with analysis of ApoC-III as a continuous variable, Tobit regression of plasma ApoC-III quartiles showed that subjects within the highest ApoC-III quartile had a significantly greater likelihood of increased CAC when compared with subjects in the lowest ApoC-III quartile (Figure 2). These results were comparable in both the combined and sex-stratified analyses for both sexes (Table 5). Consistent with these results, the presence of any amount of CAC (CAC>0) was significantly associated with higher ApoC-III levels relative to no CAC present when CAC presence or absence was treated as a dichotomous variable (odds ratio=1.33; 95% CI, 1.05–1.69; P<0.05; Table IV in the online-only Data Supplement).

View this table:
Table 5.

Association of ApoC-III With CAC Score in Multivariate Tobit Regression Model

Figure 2.
Figure 2.

Relationship of apolipoprotein C (ApoC)-III to coronary artery calcification (CAC) score stratified by ApoC-III quartile. Plasma ApoC-III distribution in studied participants was separated into quartiles and CAC score distribution was measured in each quartile (Agatston CAC scores for each ApoC-III quartile given in table below the graph). Tobit regression ratios (TRRs) were calculated after adjustment for age, race, sex, body mass index, smoking, alcohol use, systolic blood pressure, history of hypertension, glomerular filtration rate, C-reactive protein, and medication use. TRR for ApoC-III quartile 4 vs quartile 1 were compared. CI indicates confidence interval; and IQR, interquartile range. ****P<0.0001.

Discussion

In this study, we evaluated the relationship of plasma ApoC-III levels to plasma lipids, additional cardiometabolic phenotypes, and CAC in patients with T2DM. Because insulin resistance, perturbed TRL metabolism and increased CHD risk are hallmarks of T2DM, ApoC-III may play a particularly important role in risk of heart disease in this population. As anticipated, we found strong positive relationships between plasma ApoC-III and triglycerides, total cholesterol, ApoB and ApoE levels, and a negative relationship between HDL-C and ApoA-I levels. We also found a significant positive, triglyceride-dependent relationship between ApoC-III and fasting glucose and HbA1c. Finally, we demonstrate a robust association of ApoC-III levels with higher CAC scores and further show that this relationship is attenuated after adjustment for triglycerides or VLDL-C, suggesting that TRLs play an intermediary role in the relationship of ApoC-III with atherosclerosis. This study represents the largest investigation to date evaluating the relationship between plasma ApoC-III levels, markers of cardiometabolic risk, and atherosclerosis in T2DM.

Here, we further advance the proposed relationship between ApoC-III, triglycerides, and atherosclerotic burden in patients with T2DM by evaluating diabetic subjects without preexisting CHD. CAC is an established preclinical marker and predictor of clinical CHD and future cardiac events in both the general population and in patients with T2DM.31–33 It has been previously shown that CAC scores >100 robustly predict risk of coronary events in patients >7-fold relative to no CAC, as per the Agatston scoring criteria for CAC, and this relationship is consistent across different ethnicities.32 We found that when we separated subjects in our study by ApoC-III quartile, the highest ApoC-III quartile had higher CAC scores than the lowest ApoC-III quartile, whose scores were largely 0. Thus, we posit that those subjects in the highest ApoC-III quartile would possess a substantially greater risk of CAD relative to those with the lowest ApoC-III levels in our study. Previously, it was suggested that the predominant predictors of CAC progression are age and baseline CAC score beyond traditional risk factors for atherosclerosis.34 Our study here did not assess the contribution of ApoC-III to the progression of CAC, yet our finding of a robust association of ApoC-III levels with CAC score after correction for multiple important demographic and pharmacological contributors warrants study of the relationship of ApoC-III to the progression of CAC over time and subsequent influence on clinically manifest vascular disease development, particularly in T2DM.

In our analysis of ApoC-III and CAC, adjustment for plasma triglyceride levels attenuated the relationship, implying that plasma ApoC-III relates to CAC in a triglyceride-dependent manner. This finding extends those of previous smaller studies evaluating ApoC-III levels and CHD in T2DM. Onat et al35 showed in 857 subjects with metabolic syndrome that plasma ApoC-III levels positively correlated with multiple inflammatory biomarkers and in men were associated with increased incidence of CHD. Similarly, in a cohort of 188 patients with T2DM, Gervaise et al36 reported a positive relationship between both total plasma and ApoB-associated ApoC-III levels with triglycerides and with macroangiopathy and incident CHD.

We also found that, such as triglycerides, VLDL-C fully attenuated the association between ApoC-III and CAC in our study. We recently showed that VLDL-C was a predictor of CAC beyond plasma triglycerides in this study population.37 Indeed, our new findings suggest that the attenuation of the relationship between ApoC-III and CAC may have been more robust after adjusting for VLDL-C than for triglycerides alone. This suggests that ApoC-III may mediate atherosclerotic risk most specifically by contributing to the elevation of remnant cholesterol particles, such as VLDL and chylomicron remnants. This is consistent with its known physiological role in delaying the clearance of TRL remnant particles by the liver through interplay with ApoE on these particles.13,14,17 Our results suggest that inhibition of ApoC-III–mediated elevation of triglycerides and VLDL-C could reduce risk of vascular diseases in the setting of T2DM.

When taken together, our findings support decades of evidence from animal models, biochemical studies, and more recent human genetics studies showing ApoC-III as a key regulator of plasma triglycerides and CHD. Physiological studies in proatherogenic, APOC3-overexpressing mice (APOC3 transgenic; Ldlr knockout mice) showed that ApoC-III could promote atherogenesis in vivo.38 One previous genotyping study of an APOC3 variant in the Lancaster Amish and 2 recent sequencing studies in large populations identified loss-of-function variants in APOC3 that were associated with lower plasma triglycerides and reduced CAD risk.6,7,19 These 3 studies have established a direct casual genetic role for ApoC-III in mediating cardiovascular risk in humans.

Few studies have evaluated how T2DM modifies the relationship of ApoC-III to CHD risk. Crosby et al6 attempted to evaluate this in the Framingham Heart Study and the Verona Heart Study as part of their larger exome sequencing effort, which identified APOC3 loss-of-function variants associated with disease protection. They tested the association of ApoC-III levels with incident CHD (Framingham Heart Study) or with cardiovascular mortality (Verona Heart Study). They tested these associations both with a model adjusting for only age and sex or a model that corrected for these in addition to diabetes mellitus, hypertension, LDL-C, HDL-C, lipid-lowering treatment, and fasting glucose. For the Framingham Heart Study, association-testing using the second model with additional covariates including diabetes mellitus attenuated the positive relationship between ApoC-III and incident CHD seen when the first model was used. However, this finding was not replicated in the Verona Heart Study association analysis and inclusion of the additional covariates including diabetes mellitus status only modestly attenuated the association of ApoC-III with cardiovascular mortality. Most importantly, this analysis did not specifically test the contribution of diabetes mellitus to the association between ApoC-III and CHD as multiple other contributors to this relationship were included in the second model. Indeed, T2DM is a multifaceted state of metabolic dysregulation, which may include obesity and hypertriglyceridemia, 2 potential confounders to assessing whether diabetes mellitus alone impacts the relationship of ApoC-III to plasma lipids themselves or to vascular disease risk. Larger studies carefully comparing obese versus nonobese diabetics and hypertriglycerdemic versus normotriglycerdmic diabetics to each other as well as to nondiabetics will be crucial to definitively establish how each metabolic perturbation alters the relationship of ApoC-III to plasma lipids and CHD risk.

Before our study here, several smaller studies have reported that ApoC-III levels are increased with the metabolic syndrome or insulin resistance in humans. In a study of 310 patients with T2DM versus control subjects, Hiukka et al39 found higher plasma ApoC-III concentrations, higher ratios of ApoC-II-to-ApoC-III, and higher ApoC-III-to-ApoE of VLDL in T2DM than in nondiabetic subjects. In a study of Cherokee Native American youths, a population predisposed to insulin resistance and increased CHD risk, Blackett et al40 found positive relationships of apoB-bound ApoC-III to plasma triglycerides and BMI. In insulin-resistant states, higher plasma ApoC-III is robustly associated with hypertriglyceridemia. van der Ham et al41 reported higher plasma ApoC-III correlated with higher postprandial triglycerides in a study of 98 men challenged to an oral fat load. Similarly, Lee et al42 reported in a smaller study of 30 diabetic versus 30 nondiabetic subjects a correlation of total plasma ApoC-III with plasma triglycerides. Despite plasma ApoC-III association with glycemic traits and hypertriglyceridemia in insulin resistance, our data in a much larger T2DM sample than previously reported suggest limited association of ApoC-III with plasma adipokines or with anatomic measures of obesity (BMI and waist circumference) perhaps arguing against a primary ApoC-III modulation of adipose tissue per se.

Supporting the recent genetic studies suggesting ApoC-III loss-of-function is atheroprotective, the direct relationship of ApoC-III to CAC via its modulation of triglycerides and VLDL-C shown by our study implicate ApoC-III as a potential therapeutic target for reduction of vascular disease risk, especially in T2DM. Currently, statins are effective therapeutics for preventing CHD in T2DM subjects, and multiple studies have reported that statins also reduce plasma ApoC-III levels, probably through promoting the clearance of TRLs, as well as LDL from circulation.43 However, there remains an immense burden of CHD in patients who may already be maximally treated with statins, with ≈1 in 7 patients treated with statins during a 5-year period exhibiting residual cardiovascular disease.44,45 Non–HDL-C is the most significant predictor of this on-statin residual vascular risk beyond LDL-C in large meta-analyses of randomized statin trials for reduction of cardiovascular events.46 There is thus a substantial need for additional synergistic therapies to reduce other causal mediators of CHD, such as non–HDL-C. At least 1 therapy targeting ApoC-III, antisense oligonucleotides silencing hepatic APOC3 expression, is in clinical development.47 Recently, this therapy was shown to successfully reduce ApoC-III levels and plasma triglycerides in 3 patients with familial chylomicronemia syndrome, a genetic cause of profoundly elevated triglycerides because of lipoprotein lipase deficiency.48 This work provides 1 example of the use of ApoC-III inhibition for reducing triglycerides in specific clinical settings. Our results suggest there will be great interest in and need to directly evaluate the efficacy of ApoC-III–focused drugs in preventing CHD in high-risk populations particularly those insulin-resistant and T2DM.

Our study has both strengths and limitations. We report here the largest evaluation of ApoC-III levels, plasma triglycerides and other lipid and metabolic parameters, and CHD risk in T2DM subjects. Our analysis included significant proportions of non-white ethnicity and women, and we found mostly consistent results for the associations reported across these demographics, suggesting the generalizability of our findings. Limitations of our study include its cross-sectional design and lack of additional information on CHD-related outcomes in these subjects, although CAC has been demonstrated previously to be a reliable predictor of future CHD-related events in T2DM.31–33 The use of CAC in monitoring the progression of CHD after incidence and after lipid-lowering therapy is currently being debated, and thus we could not accurately predict how ApoC-III may modulate the progression or regression of disease as measured by this surrogate metric.49 A large proportion of subjects in our study were on aspirin although they were not necessarily indicated as candidates for primary prevention of cardiovascular events. Because aspirin can modulate risk of atherosclerotic disease, we did test the association of ApoC-III with CAC by Tobit regression modeling after adjusting for aspirin use and observed no attenuation in the association when it was included (data not shown). Because of limited measures and the fact that many of the subjects were on insulin therapy, we did not directly measure homeostatic models of insulin resistance in our patient population, a measure that may have supported our findings of the relationship of ApoC-III to plasma glucose. However, we note consistency in the findings between measures of fasting glucose and HbA1c within our study cohort. Although we did not measure ApoC-III levels in specific lipoprotein subclasses, we show here that total plasma ApoC-III, an easily measurable biomarker in the clinical setting, correlates with plasma triglycerides and apoB in ways that previous studies of lipoprotein-associated ApoC-III levels have suggested, whereas total plasma ApoC-III also associated positively with CAC, a predictor of CHD.

As evidence builds from human genetics and early clinical studies about the value of lowering ApoC-III to reduce cardiovascular risk, it is critical to identify specific high-risk patient populations who would benefit most from ApoC-III–targeted therapies. Here, we demonstrate convincingly that in T2DM associates with elevated cardiovascular risk factors and greater subclinical atherosclerosis in a manner related to their ApoC-III levels. Thus, therapeutic targeting of ApoC-III in T2DM may provide a powerful tool for reducing the high residual risk of atherosclerotic CHD in this population.

Sources of Funding

This work and related research was supported by K24 HL107643 to M.P. Reilly and R37 HL055323 to D.J. Rader. M.P. Reilly is also supported by R01 HL113147, R01 HL111694, R01 DK090505, and U01 HL108636. S.A. Khetarpal is supported in by the University of Pennsylvania Medical Scientist Training Program and by the F30 HL124967 fellowship from the National Institutes of Health.

Disclosures

None.

Footnotes

  • This manuscript was sent to Anne Tybjaerg-Hansen, Consulting Editor, for review by expert referees, editorial decision, and final disposition.

  • The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.115.305415/-/DC1.

  • Nonstandard Abbreviations and Acronyms
    Apo
    apolipoprotein
    CAC
    coronary artery calcification
    CHD
    coronary heart disease
    HbA1c
    hemoglobin A1c
    HDL-C
    high-density lipoprotein cholesterol
    LDL-C
    low-density lipoprotein cholesterol
    T2DM
    type 2 diabetes mellitus
    TRLs
    triglyceride-rich lipoproteins
    VLDL-C
    very low–density lipoprotein cholesterol

  • Received December 27, 2014.
  • Accepted June 2, 2015.

References

  1. 1.↵
    1. Stone NJ,
    2. Robinson JG,
    3. Lichtenstein AH,
    4. et al
    ; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S1–S45. doi: 10.1161/01.cir.0000437738.63853.7a.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Nordestgaard BG,
    2. Benn M,
    3. Schnohr P,
    4. Tybjaerg-Hansen A.
    Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299–308. doi: 10.1001/jama.298.3.299.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Sarwar N,
    2. Danesh J,
    3. Eiriksdottir G,
    4. Sigurdsson G,
    5. Wareham N,
    6. Bingham S,
    7. Boekholdt SM,
    8. Khaw KT,
    9. Gudnason V.
    Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450–458. doi: 10.1161/CIRCULATIONAHA.106.637793.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Do R,
    2. Willer CJ,
    3. Schmidt EM,
    4. et al
    . Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345–1352. doi: 10.1038/ng.2795.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Rosenson RS,
    2. Davidson MH,
    3. Hirsh BJ,
    4. Kathiresan S,
    5. Gaudet D.
    Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64:2525–2540. doi: 10.1016/j.jacc.2014.09.042.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Blood I,
    2. Crosby J,
    3. Peloso GM,
    4. et al
    ; Tg, Hdl Working Group of the Exome Sequencing Project NHL. Loss-of-function mutations in apoc3, triglycerides, and coronary disease. New Engl J Med. 2014;371:22–31.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Jørgensen AB,
    2. Frikke-Schmidt R,
    3. Nordestgaard BG,
    4. Tybjærg-Hansen A.
    Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32–41. doi: 10.1056/NEJMoa1308027.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Do R,
    2. Stitziel NO,
    3. Won HH,
    4. et al
    ; NHLBI Exome Sequencing Project. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015;518:102–106. doi: 10.1038/nature13917.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Rip J,
    2. Nierman MC,
    3. Ross CJ,
    4. Jukema JW,
    5. Hayden MR,
    6. Kastelein JJ,
    7. Stroes ES,
    8. Kuivenhoven JA.
    Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol. 2006;26:1236–1245. doi: 10.1161/01.ATV.0000219283.10832.43.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Kastelein JJ,
    2. Ordovas JM,
    3. Wittekoek ME,
    4. Pimstone SN,
    5. Wilson WF,
    6. Gagné SE,
    7. Larson MG,
    8. Schaefer EJ,
    9. Boer JM,
    10. Gerdes C,
    11. Hayden MR.
    Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women. Clin Genet. 1999;56:297–305.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Ooi EM,
    2. Barrett PH,
    3. Chan DC,
    4. Watts GF.
    Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond). 2008;114:611–624. doi: 10.1042/CS20070308.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Eisenberg S,
    2. Patsch JR,
    3. Sparrow JT,
    4. Gotto AM,
    5. Olivecrona T.
    Very low density lipoprotein. Removal of Apolipoproteins C-II and C-III-1 during lipolysis in vitro. J Biol Chem. 1979;254:12603–12608.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Aalto-Setälä K,
    2. Fisher EA,
    3. Chen X,
    4. Chajek-Shaul T,
    5. Hayek T,
    6. Zechner R,
    7. Walsh A,
    8. Ramakrishnan R,
    9. Ginsberg HN,
    10. Breslow JL.
    Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest. 1992;90:1889–1900. doi: 10.1172/JCI116066.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Aalto-Setälä K,
    2. Weinstock PH,
    3. Bisgaier CL,
    4. Wu L,
    5. Smith JD,
    6. Breslow JL.
    Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. J Lipid Res. 1996;37:1802–1811.
    OpenUrlAbstract
  15. 15.↵
    1. Ebara T,
    2. Ramakrishnan R,
    3. Steiner G,
    4. Shachter NS.
    Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest. 1997;99:2672–2681. doi: 10.1172/JCI119456.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Liu H,
    2. Talmud PJ,
    3. Lins L,
    4. Brasseur R,
    5. Olivecrona G,
    6. Peelman F,
    7. Vandekerckhove J,
    8. Rosseneu M,
    9. Labeur C.
    Characterization of recombinant wild type and site-directed mutations of apolipoprotein C-III: lipid binding, displacement of ApoE, and inhibition of lipoprotein lipase. Biochemistry. 2000;39:9201–9212.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Ginsberg HN,
    2. Brown WV.
    Apolipoprotein CIII: 42 years old and even more interesting. Arterioscler Thromb Vasc Biol. 2011;31:471–473. doi: 10.1161/ATVBAHA.110.221846.
    OpenUrlFREE Full Text
  18. 18.↵
    1. Larsson M,
    2. Vorrsjö E,
    3. Talmud P,
    4. Lookene A,
    5. Olivecrona G.
    Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J Biol Chem. 2013;288:33997–34008. doi: 10.1074/jbc.M113.495366.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Pollin TI,
    2. Damcott CM,
    3. Shen H,
    4. Ott SH,
    5. Shelton J,
    6. Horenstein RB,
    7. Post W,
    8. McLenithan JC,
    9. Bielak LF,
    10. Peyser PA,
    11. Mitchell BD,
    12. Miller M,
    13. O’Connell JR,
    14. Shuldiner AR.
    A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322:1702–1705. doi: 10.1126/science.1161524.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Chen M,
    2. Breslow JL,
    3. Li W,
    4. Leff T.
    Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res. 1994;35:1918–1924.
    OpenUrlAbstract
  21. 21.↵
    1. Reaven GM,
    2. Mondon CE,
    3. Chen YD,
    4. Breslow JL.
    Hypertriglyceridemic mice transgenic for the human apolipoprotein C-III gene are neither insulin resistant nor hyperinsulinemic. J Lipid Res. 1994;35:820–824.
    OpenUrlAbstract
  22. 22.↵
    1. Altomonte J,
    2. Cong L,
    3. Harbaran S,
    4. Richter A,
    5. Xu J,
    6. Meseck M,
    7. Dong HH.
    Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest. 2004;114:1493–1503. doi: 10.1172/JCI19992.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Claudel T,
    2. Inoue Y,
    3. Barbier O,
    4. Duran-Sandoval D,
    5. Kosykh V,
    6. Fruchart J,
    7. Fruchart JC,
    8. Gonzalez FJ,
    9. Staels B.
    Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology. 2003;125:544–555.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Barbier O,
    2. Torra IP,
    3. Sirvent A,
    4. Claudel T,
    5. Blanquart C,
    6. Duran-Sandoval D,
    7. Kuipers F,
    8. Kosykh V,
    9. Fruchart JC,
    10. Staels B.
    FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology. 2003;124:1926–1940.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Coste H,
    2. Rodríguez JC.
    Orphan nuclear hormone receptor Rev-erbalpha regulates the human apolipoprotein CIII promoter. J Biol Chem. 2002;277:27120–27129. doi: 10.1074/jbc.M203421200.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Lalloyer F,
    2. Wouters K,
    3. Baron M,
    4. Caron S,
    5. Vallez E,
    6. Vanhoutte J,
    7. Baugé E,
    8. Shiri-Sverdlov R,
    9. Hofker M,
    10. Staels B,
    11. Tailleux A.
    Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice. Arterioscler Thromb Vasc Biol. 2011;31:1573–1579. doi: 10.1161/ATVBAHA.110.220525.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Caron S,
    2. Verrijken A,
    3. Mertens I,
    4. et al
    . Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2011;31:513–519. doi: 10.1161/ATVBAHA.110.220723.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Li WW,
    2. Dammerman MM,
    3. Smith JD,
    4. Metzger S,
    5. Breslow JL,
    6. Leff T.
    Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest. 1995;96:2601–2605. doi: 10.1172/JCI118324.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Jensen MK,
    2. Bertoia ML,
    3. Cahill LE,
    4. Agarwal I,
    5. Rimm EB,
    6. Mukamal KJ.
    Novel metabolic biomarkers of cardiovascular disease. Nat Rev Endocrinol. 2014;10:659–672. doi: 10.1038/nrendo.2014.155.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Haas ME,
    2. Attie AD,
    3. Biddinger SB.
    The regulation of ApoB metabolism by insulin. Trends Endocrinol Metab. 2013;24:391–397. doi: 10.1016/j.tem.2013.04.001.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Raggi P,
    2. Shaw LJ,
    3. Berman DS,
    4. Callister TQ.
    Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol. 2004;43:1663–1669. doi: 10.1016/j.jacc.2003.09.068.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Detrano R,
    2. Guerci AD,
    3. Carr JJ,
    4. Bild DE,
    5. Burke G,
    6. Folsom AR,
    7. Liu K,
    8. Shea S,
    9. Szklo M,
    10. Bluemke DA,
    11. O’Leary DH,
    12. Tracy R,
    13. Watson K,
    14. Wong ND,
    15. Kronmal RA.
    Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358:1336–1345. doi: 10.1056/NEJMoa072100.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Kondos GT,
    2. Hoff JA,
    3. Sevrukov A,
    4. Daviglus ML,
    5. Garside DB,
    6. Devries SS,
    7. Chomka EV,
    8. Liu K.
    Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation. 2003;107:2571–2576. doi: 10.1161/01.CIR.0000068341.61180.55.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Erbel R,
    2. Lehmann N,
    3. Churzidse S,
    4. et al
    ; Heinz Nixdorf Recall Study Investigators. Progression of coronary artery calcification seems to be inevitable, but predictable - results of the Heinz Nixdorf Recall (HNR) study. Eur Heart J. 2014;35:2960–2971. doi: 10.1093/eurheartj/ehu288.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Onat A,
    2. Hergenç G,
    3. Sansoy V,
    4. Fobker M,
    5. Ceyhan K,
    6. Toprak S,
    7. Assmann G.
    Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis. 2003;168:81–89.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Gervaise N,
    2. Garrigue MA,
    3. Lasfargues G,
    4. Lecomte P.
    Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes. Diabetologia. 2000;43:703–708. doi: 10.1007/s001250051366.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Prenner SB,
    2. Mulvey CK,
    3. Ferguson JF,
    4. Rickels MR,
    5. Bhatt AB,
    6. Reilly MP.
    Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides. Atherosclerosis. 2014;236:244–250. doi: 10.1016/j.atherosclerosis.2014.07.008.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Masucci-Magoulas L,
    2. Goldberg IJ,
    3. Bisgaier CL,
    4. Serajuddin H,
    5. Francone OL,
    6. Breslow JL,
    7. Tall AR.
    A mouse model with features of familial combined hyperlipidemia. Science. 1997;275:391–394.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Hiukka A,
    2. Fruchart-Najib J,
    3. Leinonen E,
    4. Hilden H,
    5. Fruchart JC,
    6. Taskinen MR.
    Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetologia. 2005;48:1207–1215. doi: 10.1007/s00125-005-1753-z.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Blackett PR,
    2. Blevins KS,
    3. Quintana E,
    4. Stoddart M,
    5. Wang W,
    6. Alaupovic P,
    7. Lee ET.
    ApoC-III bound to apoB-containing lipoproteins increase with insulin resistance in Cherokee Indian youth. Metabolism. 2005;54:180–187. doi: 10.1016/j.metabol.2004.08.010.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. van der Ham RL,
    2. Alizadeh Dehnavi R,
    3. Berbée JF,
    4. Putter H,
    5. de Roos A,
    6. Romijn JA,
    7. Rensen PC,
    8. Tamsma JT.
    Plasma apolipoprotein CI and CIII levels are associated with increased plasma triglyceride levels and decreased fat mass in men with the metabolic syndrome. Diabetes Care. 2009;32:184–186. doi: 10.2337/dc08-1330.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Lee SJ,
    2. Moye LA,
    3. Campos H,
    4. Williams GH,
    5. Sacks FM.
    Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease. Atherosclerosis. 2003;167:293–302.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Dallinga-Thie GM,
    2. Berk-Planken II,
    3. Bootsma AH,
    4. Jansen H
    ; Diabetes Atorvastatin Lipid intervention (DALI) Study Group. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides. Diabetes Care. 2004;27:1358–1364.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Baigent C,
    2. Keech A,
    3. Kearney PM,
    4. Blackwell L,
    5. Buck G,
    6. Pollicino C,
    7. Kirby A,
    8. Sourjina T,
    9. Peto R,
    10. Collins R,
    11. Simes R
    ; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278. doi: 10.1016/S0140-6736(05)67394-1.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Baigent C,
    2. Blackwell L,
    3. Emberson J,
    4. Holland LE,
    5. Reith C,
    6. Bhala N,
    7. Peto R,
    8. Barnes EH,
    9. Keech A,
    10. Simes J,
    11. Collins R
    ; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. doi: 10.1016/S0140-6736(10)61350-5.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Boekholdt SM,
    2. Arsenault BJ,
    3. Mora S,
    4. et al
    . Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307:1302–1309. doi: 10.1001/jama.2012.366.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Graham MJ,
    2. Lee RG,
    3. Bell TA III.,
    4. Fu W,
    5. Mullick AE,
    6. Alexander VJ,
    7. Singleton W,
    8. Viney N,
    9. Geary R,
    10. Su J,
    11. Baker BF,
    12. Burkey J,
    13. Crooke ST,
    14. Crooke RM.
    Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112:1479–1490. doi: 10.1161/CIRCRESAHA.111.300367.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Gaudet D,
    2. Brisson D,
    3. Tremblay K,
    4. Alexander VJ,
    5. Singleton W,
    6. Hughes SG,
    7. Geary RS,
    8. Baker BF,
    9. Graham MJ,
    10. Crooke RM,
    11. Witztum JL.
    Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371:2200–2206. doi: 10.1056/NEJMoa1400284.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Puri R,
    2. Nicholls SJ,
    3. Shao M,
    4. Kataoka Y,
    5. Uno K,
    6. Kapadia SR,
    7. Tuzcu EM,
    8. Nissen SE.
    Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol. 2015;65:1273–1282. doi: 10.1016/j.jacc.2015.01.036.
    OpenUrlCrossRefPubMed

Significance

Strong evidence from epidemiology, human genetics, and animal physiological studies support a role for the protein apolipoprotein C (ApoC)-III in promoting risk of coronary heart disease through increasing plasma triglycerides. The relationship of ApoC-III to risk of heart disease in type 2 diabetics, a population already at elevated risk of heart attacks, has been studied limitedly. In the largest cross-sectional study of blood ApoC-III levels in type 2 diabetics to date, we measure the relationship of ApoC-III to plasma lipids, glucose and metabolic traits, and coronary artery calcification, a noninvasive surrogate measure of atherosclerosis. We find a positive relationship between ApoC-III levels to triglycerides and coronary artery calcification in patients with T2DM, supporting a role for ApoC-III inhibition in these patients as a means to reduce vascular risk.

View Abstract

This Issue

Jump to

Article Tools

Share this Article

  • Email
  • Plasma Apolipoprotein C-III Levels, Triglycerides, and Coronary Artery Calcification in Type 2 DiabeticsSignificance
    Arman Qamar, Sumeet A. Khetarpal, Amit V. Khera, Atif Qasim, Daniel J. Rader and Muredach P. Reilly
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2015;35:1880-1888, originally published June 11, 2015
    https://doi.org/10.1161/ATVBAHA.115.305415
    Permalink:
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects